There is a growing interest in the use of thiopurines for inflammatory bowel disease. Pharmacogenetic insights suggest that the genetic profile of thiopurine S-methyltransferase and inosine triphosphate pyrophosphatase may affect the clinical response to thiopurines. This is a review on the pharmacogenetics of these enzymes and highlights difficulties that impede prior-to-treat pharmacogenetic testing for the thiopurines in practice.
|Number of pages||3|
|Journal||Journal of Pharmacy Practice and Research|
|Publication status||Published - 1 Sep 2005|